Norgine: Agility & Adaptation
How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player…
The Winncare group is working with specialists in the (para)medical field to develop a range of medical equipment adapted for people in care, the elderly, disabled people and health and social care professionals. Their aim is to improve services and people’s quality of care and life by offering efficient and high quality products and services. Winncare has positioned itself to be in the market of preventative care, especially patients at risk of bedsores or loss of autonomy. Today the focus is on expanding its position throughout Europe. The objective of the company is to reach a turnover of 100 million Euros (USD 109 million) from their current revenues of 45 million Euros (USD 48 million) over the course of five years, primarily through organic growth as well as strategic acquisition.
Contact
Regus – Groupe Winncare
Bureaux 1507A11507B
La Grande Arche – Paroi Nord
90244 La Defense Cedex
How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player…
When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads…
France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability…
As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site…
As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition…
Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33…
Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl…
Born from personal tragedy, Imagine for Margo has evolved into a pan-European force reshaping how childhood cancers are researched, funded, and brought to the policy agenda. Drawing on a parent’s…
Raymond Le Moign leads one of Europe’s largest university hospital centres at a moment when healthcare systems are being forced to rethink how they organise care, innovation, and accountability. Drawing…
A new chapter in vital organ care is unfolding as Vantive establishes its identity as an independent, purpose-driven leader in kidney care. With Trushar Patel stepping into an expanded leadership…
Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this…
Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new…
See our Cookie Privacy Policy Here
